ADMA Biologics Inc vs American Tower Corp — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while American Tower Corp trades at $169.8 (market cap $79.00B). The key difference: American Tower Corp is far larger — about 35.6× ADMA Biologics Inc's market cap, and American Tower Corp pays a 4.12% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | AMT | |
|---|---|---|
Market Cap | $2.22B | $79.00B |
Sector | Health | Real Estate |
52-Week High | $20.38 | $211.88 |
52-Week Low | $7.60 | $162.11 |
Enterprise Value | $2.29B | $122.53B |
Dividend Yield | — | 4.12% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.
American Tower Corporation (AMT) trades at $170.48, up 0.81% with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals despite analyst optimism, with 79.6% buy ratings and a $206.17 consensus price target representing 21% upside potential. Recent Q2 2026 results demonstrated accelerated lease contract growth and raised full-year guidance.
AMT presents a compelling investment case with strong revenue visibility from telecom infrastructure demand and 5G/6G expansion cycles. However, high debt levels and interest rate sensitivity pose significant risks. The stock offers defensive characteristics through recurring revenue streams but faces headwinds from DISH Network churn and capital expenditure requirements.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →